From the Field — JVIB Extract
Since From the Field features do not have abstracts, we have provided an extract of the beginning of the text.
Gene therapy clinical trial underway for Stargardt's disease
The first-ever clinical trial of gene therapy for Stargardt's disease, a juvenile form of macular degeneration, is now underway at Oregon Health and Science University (OHSU) in Portland. Known as StarGen, the treatment is being developed by Oxford Biomedica, a biopharmaceutical company in the United Kingdom, with financial support from the Foundation Fighting Blindness.
Please log in if you wish to make a comment.
There are 0 comments on this article.
If you are a JVIB subscriber, please log in below. If you are an AER member, JVIB is part of your membership benefit: please visit AER's website to access JVIB.
Not yet a subscriber? Here are some options:
Purchase this individual article
Prefer not to subscribe?
Read FREE JVIB content or check out what JVIB has to offer.